NZ504291A - Compositions and methods for targeted delivery of factors - Google Patents

Compositions and methods for targeted delivery of factors

Info

Publication number
NZ504291A
NZ504291A NZ504291A NZ50429198A NZ504291A NZ 504291 A NZ504291 A NZ 504291A NZ 504291 A NZ504291 A NZ 504291A NZ 50429198 A NZ50429198 A NZ 50429198A NZ 504291 A NZ504291 A NZ 504291A
Authority
NZ
New Zealand
Prior art keywords
factors
compositions
methods
targeted delivery
bound
Prior art date
Application number
NZ504291A
Other languages
English (en)
Inventor
Lawrence Tamarkin
Giulio F Paciotti
Original Assignee
Cytimmune Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/966,940 external-priority patent/US6274552B1/en
Application filed by Cytimmune Sciences Inc filed Critical Cytimmune Sciences Inc
Publication of NZ504291A publication Critical patent/NZ504291A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
NZ504291A 1997-11-10 1998-11-10 Compositions and methods for targeted delivery of factors NZ504291A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/966,940 US6274552B1 (en) 1993-03-18 1997-11-10 Composition and method for delivery of biologically-active factors
US7581198P 1998-02-24 1998-02-24
US8669698P 1998-05-26 1998-05-26
US10745598P 1998-11-06 1998-11-06
PCT/US1998/023931 WO1999024077A2 (en) 1997-11-10 1998-11-10 Compositions and methods for targeted delivery of biologically-active factors

Publications (1)

Publication Number Publication Date
NZ504291A true NZ504291A (en) 2002-10-25

Family

ID=27491221

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ504291A NZ504291A (en) 1997-11-10 1998-11-10 Compositions and methods for targeted delivery of factors

Country Status (9)

Country Link
US (1) US20090035265A1 (enExample)
EP (1) EP1044022B1 (enExample)
JP (1) JP4620243B2 (enExample)
AT (1) ATE320270T1 (enExample)
AU (1) AU760035B2 (enExample)
CA (1) CA2309604C (enExample)
DE (1) DE69833876T2 (enExample)
NZ (1) NZ504291A (enExample)
WO (1) WO1999024077A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010055581A1 (en) 1994-03-18 2001-12-27 Lawrence Tamarkin Composition and method for delivery of biologically-active factors
WO1999024066A2 (en) * 1997-11-10 1999-05-20 Cytimmune Sciences, Inc. Methods and compositions for enhancing immune response and for the production of in vitro mabs
US6407218B1 (en) 1997-11-10 2002-06-18 Cytimmune Sciences, Inc. Method and compositions for enhancing immune response and for the production of in vitro mabs
US7229841B2 (en) 2001-04-30 2007-06-12 Cytimmune Sciences, Inc. Colloidal metal compositions and methods
JP2009286808A (ja) * 1997-11-10 2009-12-10 Cytimmune Sciences Inc 生物学的に活性な因子の標的化された送達のための組成物および方法
CA2448607C (en) 2001-04-30 2013-01-22 Cytimmune Sciences, Inc. Colloidal metal compositions and methods
EP1694301A4 (en) * 2003-12-02 2009-11-18 Cytimmune Sciences Inc METHOD AND COMPOSITIONS FOR THE PRODUCTION OF MONOCLONAL ANTIBODIES
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
US8877156B2 (en) 2007-06-26 2014-11-04 New York University Contrast agents anchored by thiols on nanoparticles
EP2200932A4 (en) * 2007-09-21 2014-09-10 Cytimmune Sciences Inc NANOTHERAPEUTIC COLLOIDAL METAL COMPOSITIONS AND METHODS
EP2219458B1 (en) 2007-11-08 2015-07-15 Cytimmune Sciences, Inc. Compositions and methods for generating antibodies
WO2009140408A2 (en) 2008-05-13 2009-11-19 University Of Kansas Metal abstraction peptide (map) tag and associated methods
WO2013181461A2 (en) 2012-06-01 2013-12-05 University Of Kansas Metal abstraction peptide with superoxide dismutase activity
US10064940B2 (en) 2013-12-11 2018-09-04 Siva Therapeutics Inc. Multifunctional radiation delivery apparatus and method

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963354A (en) * 1987-01-21 1990-10-16 Genentech, Inc. Use of tumor necrosis factor (TNF) as an adjuvant
US5047523A (en) * 1988-08-02 1991-09-10 Ortho Diagnostic Systems Inc. Nucleic acid probe for detection of neisseria gonorrhoea
US5248772A (en) * 1992-01-29 1993-09-28 Coulter Corporation Formation of colloidal metal dispersions using aminodextrans as reductants and protective agents
CA2158475C (en) * 1993-03-18 2009-06-02 Lawrence Tamarkin Composition and method for reducing toxicity of biologically-active factors
JPH07227299A (ja) * 1994-02-14 1995-08-29 Kyoto Daiichi Kagaku:Kk Ｄｎａの特定塩基配列の検出方法及びその装置
US5521289A (en) * 1994-07-29 1996-05-28 Nanoprobes, Inc. Small organometallic probes
US5686578A (en) * 1994-08-05 1997-11-11 Immunomedics, Inc. Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
WO1996040245A1 (en) * 1995-06-07 1996-12-19 Immunomedics, Inc. Improved delivery of diagnostic and therapeutic agents to a target site
AU2610097A (en) * 1996-04-10 1997-10-29 Sangstat Medical Corporation Cytomodulating conjugates of members of specific binding pairs
DE19622628A1 (de) * 1996-06-05 1997-12-11 Boehringer Mannheim Gmbh Stabilisierung von Metallkonjugaten
US6294378B1 (en) * 1996-07-26 2001-09-25 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
US6395276B1 (en) * 1997-05-02 2002-05-28 Immunomedics, Inc. Immunotoxins directed against malignant cells
DE19726186A1 (de) * 1997-06-20 1998-12-24 Boehringer Ingelheim Int Komplexe für den Transport von Nukleinsäure in höhere eukaryotische Zellen
WO2005072893A1 (en) * 2004-01-28 2005-08-11 Cytimmune Sciences, Inc. Functionalized colloidal metal compositions and methods
US20060185027A1 (en) * 2004-12-23 2006-08-17 David Bartel Systems and methods for identifying miRNA targets and for altering miRNA and target expression

Also Published As

Publication number Publication date
ATE320270T1 (de) 2006-04-15
AU760035B2 (en) 2003-05-08
EP1044022B1 (en) 2006-03-15
AU1394099A (en) 1999-05-31
CA2309604C (en) 2010-01-12
JP4620243B2 (ja) 2011-01-26
WO1999024077A3 (en) 1999-10-07
EP1044022A2 (en) 2000-10-18
CA2309604A1 (en) 1999-05-20
DE69833876D1 (de) 2006-05-11
WO1999024077A2 (en) 1999-05-20
DE69833876T2 (de) 2007-05-24
US20090035265A1 (en) 2009-02-05
JP2001522818A (ja) 2001-11-20

Similar Documents

Publication Publication Date Title
NZ504291A (en) Compositions and methods for targeted delivery of factors
PT935465E (pt) Compostos novos de imidazole substituido
IL125223A0 (en) Novel substituted imidazole compounds
AU1378499A (en) Methods for treating prostate tumors using radioactive compositions
CA2413190A1 (en) Methods for treating rheumatic diseases using a soluble ctla4 molecule
DE69626513D1 (en) Imidazolverbindungen
DK1144472T3 (da) Vandige reaktive spartelmasser (II)
ES2109495T3 (es) Tioureas sustituidas utilizadas como agentes quelantes bifuncionales.
AU690315B2 (en) Metal complexes with charged linker
UA85993C2 (ru) Конъюгат, который содержит бактериальный суперантиген и антительную составную, фармацевтическая композиция, которая его содержит, и способ лечения рака у млекопитающего
FR2781218B1 (fr) Compositions pharmaceutiques comprenant des 2-quinolones
DE69838979D1 (de) Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumoren
AU9102198A (en) Indole-3-carbinol, diindolylmethane and substituted analogs as antiestrogens
NO20015785D0 (no) I dets vesentlige oljefrie cyklosporinsammensetninger
AU1934495A (en) Formulations for il-11
AU9021298A (en) Agmatine as a treatment for neuropathic pain
WO2003072754A3 (en) Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
GR3024667T3 (en) Cosmetical or pharmaceutical compositions comprising deacylated glycerophospholipids for topical use.
CA2296560A1 (en) Amino acid derivatives useful to treat stroke
AU4944197A (en) Chiral ferrocenyls
AU3251597A (en) Composition and methods for modulating the length of telomeres
WO2001012607A3 (fr) Compositions pharmaceutiques comprenant des 4-quinolones pour le traitement des cancers
WO2000061786A3 (en) Antisense modulation of pdk-1 expression
PL342541A1 (en) Fungicides
WO2001068066A3 (en) A composition comprising camptothecin or a camptothecin derivative and an alkylating agent for the treatment of cancer

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired